Bayer's Vividion secures rights to world's only clinical-stage WRN inhibitor from partner Roche
Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only Werner helicase inhibitor to have made it into the clinic.
Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only Werner helicase inhibitor to have made it into the clinic.
